DEHP, cord-blood methylation, and early traits

What the study says

Plain-English summary

Researchers studied 847 children in the Barwon Infant Study and tested whether DNA methylation measured in cord blood sat on the statistical pathway between prenatal DEHP exposure and later symptom scores.

A DEHP-associated methylation profile and a 531-gene co-methylation network each mediated part of the observed associations. The network included neural-cell markers, neurodevelopmental risk genes, and targets of endocrine receptors linked to DEHP.

The team checked selected methylation findings in two smaller independent datasets. That supports the biological signal, but it does not turn an observational cohort into proof that DEHP caused a diagnosis.

Why it matters

Context

This study adds a plausible epigenetic pathway to a literature that remains mixed across cohorts. It is useful mechanistic evidence, not a way to predict autism or ADHD in an individual child.

What it cannot prove

Limitations

The exposure-outcome analysis was observational, symptoms were measured at ages two and four rather than treated as clinical diagnoses, and mediation models depend on causal assumptions that cannot all be tested. The independent datasets checked selected methylation results, not the complete exposure-to-symptom pathway.

Proportionate next steps

Practical actions

• Use proportionate pregnancy exposure-reduction steps without promising a neurodevelopmental outcome.
• Do not use a product purchase as prevention or treatment for autism or ADHD.
• Read this result alongside the large ECHO study's mostly null mixture findings and other cohorts with mixed results.

Read it yourself

Original source

Prenatal exposure to the plasticizer DEHP increases the likelihood of early-life autism and ADHD symptoms through epigenetic programming

DOI: 10.1016/j.medj.2026.101291